Curated News
By: NewsRamp Editorial Staff
January 29, 2026
Soligenix Advances Novel Light Therapy for Hard-to-Diagnose Skin Cancer
TLDR
- Soligenix's HyBryte therapy offers a competitive edge by providing targeted CTCL treatment with visible light, reducing safety risks compared to traditional ultraviolet therapies.
- HyBryte works as a visible light-activated photodynamic therapy that targets malignant T-cells in skin while minimizing damage to surrounding healthy tissue through red-yellow spectrum activation.
- This therapy makes the world better by offering safer, more effective treatment for early-stage CTCL patients, addressing critical gaps in rare disease care.
- Soligenix's novel approach uses synthetic hypericin activated by visible light, showing statistically significant efficacy in reducing CTCL lesions in clinical trials.
Impact - Why it Matters
This development matters because CTCL is notoriously difficult to diagnose in its early stages, often leading to delayed treatment and poorer outcomes for patients. Current ultraviolet-based phototherapies carry significant long-term safety risks, including increased cancer risk with cumulative exposure. HyBryte's visible light activation represents a potentially safer, more targeted approach that could transform treatment for this rare but devastating cancer. For the broader rare disease community, Soligenix's progress demonstrates how specialized biopharmaceutical companies can address critical gaps in treatment where larger pharmaceutical firms may not invest. The company's dual focus on both rare diseases and public health threats (through its vaccine programs) shows a comprehensive approach to addressing significant medical challenges that affect vulnerable populations worldwide.
Summary
Cutaneous T-cell lymphoma (CTCL), recognized as one of the most challenging cancers to diagnose early, may soon have a more effective treatment option thanks to innovative work by Soligenix Inc. (NASDAQ: SNGX). The late-stage biopharmaceutical company is advancing HyBryte™ (also known as synthetic hypericin or SGX301), a novel photodynamic therapy designed specifically for early-stage CTCL. Unlike traditional ultraviolet-based treatments that carry long-term safety risks, HyBryte is activated by visible light in the red-yellow spectrum, allowing targeted treatment of malignant T-cells in the skin while minimizing damage to surrounding healthy tissue. Clinical data reported by Soligenix indicate that HyBryte has demonstrated statistically significant efficacy in reducing CTCL lesions in patients with early-stage disease, addressing a critical gap in rare disease treatment.
Soligenix's efforts to develop therapies for rare diseases with unmet medical needs extend beyond CTCL through its Specialized BioTherapeutics business segment. The company is also expanding synthetic hypericin into psoriasis treatment and developing first-in-class innate defense regulator technology for inflammatory diseases. Additionally, Soligenix's Public Health Solutions business segment includes vaccine programs targeting ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 prevention through its CiVax™ candidate. These programs incorporate the company's proprietary heat stabilization platform technology, ThermoVax®, and have been supported by government grants and contracts from agencies including NIAID, DTRA, and BARDA.
The news about Soligenix's progress was featured in an article that can be viewed at https://ibn.fm/pnI2N, published by BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology and life sciences developments. BioMedWire provides comprehensive distribution services including article syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers. For further information about Soligenix's developments, investors can visit the company's newsroom at https://ibn.fm/SNGX or explore the full range of BioMedWire's corporate communications solutions at their website.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Advances Novel Light Therapy for Hard-to-Diagnose Skin Cancer
